Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis

Background. Coagulation disorders in patients with liver cirrhosis are a common clinical problem. Cirrhosis should be considered a state of impaired blood clotting or an imbalance of the whole coagulation system. Cirrhosis-induced coagulopathy encompasses disturbances in both the procoagulant and an...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomasz Mikuła, Joanna Kozłowska, Wojciech Stańczak, Mariusz Sapuła, Aleksandra Różyk, Alicja Wiercińska-Drapało
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2018/3287491
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850175100194652160
author Tomasz Mikuła
Joanna Kozłowska
Wojciech Stańczak
Mariusz Sapuła
Aleksandra Różyk
Alicja Wiercińska-Drapało
author_facet Tomasz Mikuła
Joanna Kozłowska
Wojciech Stańczak
Mariusz Sapuła
Aleksandra Różyk
Alicja Wiercińska-Drapało
author_sort Tomasz Mikuła
collection DOAJ
description Background. Coagulation disorders in patients with liver cirrhosis are a common clinical problem. Cirrhosis should be considered a state of impaired blood clotting or an imbalance of the whole coagulation system. Cirrhosis-induced coagulopathy encompasses disturbances in both the procoagulant and anticoagulant systems. This mechanism may promote the development of thrombosis with portal vein thrombosis (PVT), which is considered an obstacle to orthotopic liver transplantation (OLT). We assessed serum ADAMTS-13 levels in patients with decompensated liver cirrhosis, with and without PVT. Material and Methods. Serum ADAMTS-13 levels, age, platelet count (PLT), and INR (international normalized ratio) were evaluated in (n=64) patients with liver cirrhosis either with PVT (group 1, n=31) or without PVT (group 2, n=33). The results were compared with those from healthy volunteers (group 3, n=37). Liver cirrhosis was based on Desmet’s classification of chronic hepatitis in liver biopsy stage ≥ 3 or liver elastography F-score ≥ 3. Serum ADAMTS-13 levels were measured with Quantikine® ELISA Human ADAMTS13 Immunoassay, R&D Systems Inc. We used Welch’s F-test, Games-Howell, one-way ANOVA, Bonferroni test, and logistic regression to determine whether ADAMTS-13 levels were a predictor that was independent of MELD and Child-Pugh scores. All results (P<0.05) were considered statistically significant. Results. The mean serum ADAMTS-13 level in patients with PVT was significantly lower than that in patients without PVT (P=0.001) and controls (P=0.001). The mean serum ADAMTS-13 level in patients without PVT was significantly lower than that in controls (P=0.001). ADAMTS-13 levels were significantly associated with PVT accounting for the Child-Pugh or MELD score in the logistic regression model. Conclusions. Low serum ADAMTS-13 levels can be a useful indicator of portal thrombosis in patients with decompensated liver cirrhosis irrespective of Child-Pugh or MELD scores. Further research is needed to determine whether ADAMTS-13 levels will find use in everyday clinical practice.
format Article
id doaj-art-d746f5e5ce164db49f6ebfbe00058ecb
institution OA Journals
issn 1687-6121
1687-630X
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-d746f5e5ce164db49f6ebfbe00058ecb2025-08-20T02:19:31ZengWileyGastroenterology Research and Practice1687-61211687-630X2018-01-01201810.1155/2018/32874913287491Serum ADAMTS-13 Levels as an Indicator of Portal Vein ThrombosisTomasz Mikuła0Joanna Kozłowska1Wojciech Stańczak2Mariusz Sapuła3Aleksandra Różyk4Alicja Wiercińska-Drapało5Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Warsaw, PolandDepartment of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Warsaw, PolandDepartment of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Warsaw, PolandDepartment of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Warsaw, PolandScience Students’ Society of the Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Warsaw, PolandDepartment of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Warsaw, PolandBackground. Coagulation disorders in patients with liver cirrhosis are a common clinical problem. Cirrhosis should be considered a state of impaired blood clotting or an imbalance of the whole coagulation system. Cirrhosis-induced coagulopathy encompasses disturbances in both the procoagulant and anticoagulant systems. This mechanism may promote the development of thrombosis with portal vein thrombosis (PVT), which is considered an obstacle to orthotopic liver transplantation (OLT). We assessed serum ADAMTS-13 levels in patients with decompensated liver cirrhosis, with and without PVT. Material and Methods. Serum ADAMTS-13 levels, age, platelet count (PLT), and INR (international normalized ratio) were evaluated in (n=64) patients with liver cirrhosis either with PVT (group 1, n=31) or without PVT (group 2, n=33). The results were compared with those from healthy volunteers (group 3, n=37). Liver cirrhosis was based on Desmet’s classification of chronic hepatitis in liver biopsy stage ≥ 3 or liver elastography F-score ≥ 3. Serum ADAMTS-13 levels were measured with Quantikine® ELISA Human ADAMTS13 Immunoassay, R&D Systems Inc. We used Welch’s F-test, Games-Howell, one-way ANOVA, Bonferroni test, and logistic regression to determine whether ADAMTS-13 levels were a predictor that was independent of MELD and Child-Pugh scores. All results (P<0.05) were considered statistically significant. Results. The mean serum ADAMTS-13 level in patients with PVT was significantly lower than that in patients without PVT (P=0.001) and controls (P=0.001). The mean serum ADAMTS-13 level in patients without PVT was significantly lower than that in controls (P=0.001). ADAMTS-13 levels were significantly associated with PVT accounting for the Child-Pugh or MELD score in the logistic regression model. Conclusions. Low serum ADAMTS-13 levels can be a useful indicator of portal thrombosis in patients with decompensated liver cirrhosis irrespective of Child-Pugh or MELD scores. Further research is needed to determine whether ADAMTS-13 levels will find use in everyday clinical practice.http://dx.doi.org/10.1155/2018/3287491
spellingShingle Tomasz Mikuła
Joanna Kozłowska
Wojciech Stańczak
Mariusz Sapuła
Aleksandra Różyk
Alicja Wiercińska-Drapało
Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis
Gastroenterology Research and Practice
title Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis
title_full Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis
title_fullStr Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis
title_full_unstemmed Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis
title_short Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis
title_sort serum adamts 13 levels as an indicator of portal vein thrombosis
url http://dx.doi.org/10.1155/2018/3287491
work_keys_str_mv AT tomaszmikuła serumadamts13levelsasanindicatorofportalveinthrombosis
AT joannakozłowska serumadamts13levelsasanindicatorofportalveinthrombosis
AT wojciechstanczak serumadamts13levelsasanindicatorofportalveinthrombosis
AT mariuszsapuła serumadamts13levelsasanindicatorofportalveinthrombosis
AT aleksandrarozyk serumadamts13levelsasanindicatorofportalveinthrombosis
AT alicjawiercinskadrapało serumadamts13levelsasanindicatorofportalveinthrombosis